INTRODUCTION
The clinical behavior of patients with chronic lymphocytic leukemia (CLL) is heterogeneous. Whereas some patients have indolent disease and lack diseaserelated complications for many years, others develop progressive and/or symptomatic disease requiring therapy within a relatively short time after diagnosis. Early treatment of the former could place patients at risk for therapy-related complications that might compromise their quality of life and/or survival 1, 2 . Defining markers that reliably can stratify patients into groups with good-risk or poor-risk disease could facilitate clinical trials evaluating the potential benefit of early treatment.
Several markers each can segregate patients into subgroups with different rates of disease progression. The expression of unmutated immunoglobulin heavy chain variable region genes (IGHV) predicts more aggressive clinical behavior [3] [4] [5] [6] [7] [8] , as does leukemia-cell expression of CD38 3, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Gene expression analyses found that CLL cells with unmutated IGHV (U-IGHV) differed from CLL cells with mutated IGHV (M-IGHV) in the expression levels of a relatively small subset of genes, one of which encodes the zeta-chain associated protein of 70kD (ZAP-70), an intracellular tyrosine kinase involved in T cell-receptor signaling 18, 19 . Measurements of this intracellular protein can be used as a surrogate marker for expression of U-IGHV [20] [21] [22] [23] [24] [25] 38, 39 . We used recursive partitioning on flow cytometry and clinical data to define the optimal threshold for designating a sample as CD38-positive among samples collected from a test cohort of 307 patients with CLL who previously were characterized for expression of ZAP-70 and IGHV 22 . Using data-defined criteria for designating a sample positive for CD38 or ZAP-70, we assessed the relative value of CD38, ZAP-70, or use For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From of U-IGHV in predicting the time to initial treatment of patients in an independent validation cohort of 705 CLL patients followed by the CLL Research Consortium (CRC).
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MATERIALS AND METHODS

Patients Samples And Cell-Processing
Blood was obtained from CLL patients enrolled in the CRC upon written informed consent. Blood mononuclear cells were prepared using Ficoll-Hypaque 1077 (Sigma, St. Louis, MO) and suspended in fetal-calf serum containing 10% dimethylsulfoxide for storage in liquid nitrogen 22 . The IRB of UCSD has reviewed and approved this study in accordance with the requirements of the Code of Federal Regulations on the Protection of Human Subjects and the Declaration of Helsinki.
Patient Characteristics
The test cohort was comprised of 307 CLL patients (201 males (65%) and 106 females (35%)) who had a median age at diagnosis of 52 years (range 30-77 years). The validation cohort was comprised of 705 CLL patients (466 males (66%) and 239 females (34%)) who had a median age at diagnosis of 56 years (range 27-83 years).
The Rai stage was assessed when the blood sample was collected. The distribution of patients with modified Rai stage (e.g. low-risk (stage 0), intermediate-risk (stages I and II), or high-risk (stages III and IV) disease was 20%, 50%, or 30%, respectively, in the test cohort, and 22%, 47%, or 31%, respectively, in the validation cohort. The median follow-up period from sample collection to last follow-up was 5.4 years.
Patients received treatment when they developed symptomatic and/or progressive disease, as per NCI-working-group criteria 26 . Patients confirmed to have remained untreated were censored for this endpoint. Eighty-four patients in the test cohort (27%) and 184 patients in the validation cohort (26%) received treatment for CLL For personal use only. on October 3, 2017. by guest www.bloodjournal.org From before sample collection. For these patients, the median time from diagnosis to initial treatment was 1.8 years and 1.5 years for the test and the validation cohorts, respectively. Sixty-nine of the 223 untreated patients in the test cohort (31%) and 172 of the 521 untreated patients in the validation cohort (33%) received treatment after the sample was collected. For these patients, the median time from diagnosis to first treatment was 4.0 years and 3.6 years, respectively. Collectively, a total of 356 of the 705 patients in the validation cohort (50%) received therapy for CLL, of which 184 of 705 were treated prior sample collection and 172 of 705 were treated after sample collection.
Clinical Database
All the clinical data was captured via the Tissue-Core-Management-System (TCMS).
We used closed data fields to assess the date of diagnosis, date of initial treatment, and clinical status of each patient 22 . A multiple closed unique patient identifier system was used that complied with the Health Insurance Portability and Accountability Act.
Assays For ZAP-70 And CD38
We performed flow cytometry to detect expression of ZAP-70 on cryopreserved samples of each patient in the validation cohort (N=705) 22 . CLL cells also were analyzed for CD19, CD20, CD23, and CD38, using mAbs conjugated to allophycocyanin (APC), 
Assessing IGHV Mutation Status And Genomic Alterations
We analyzed the IGHV expressed by the CLL cells of each member of the validation cohort 22 . Sequences with less than 98% homology with the corresponding germ line IGHV were considered mutated. Fluorescent in situ hybridization (FISH) was performed on interphase nuclei of blood lymphocytes 6
RESULTS
Defining The Threshold For CD38 In The Test Cohort
We determined the optimal cut-off for designating a CLL sample as CD38-positive that best could segregate patients in the test cohort of 307 patients who had short versus long median times to treatment, using recursive partitioning and the log-rank test on flow cytometry and clinical data similar to how we defined the ZAP-70 threshold with this same cohort 22 . The optimal threshold was when 34% or more of the CLL cells had fluorescence above the background-fluorescence threshold. Using this threshold, patients in the test cohort who had CLL cells that were classified as being CD38-negative had a median time to first treatment of 7.8 years, whereas patients with CD38-positive CLL cells had a median time to first treatment of 3.4 years (p<0.001).
Prognostic Value Of CD38, ZAP-70, And IGHV Mutation StatusIn The Validation Cohort
We applied these data-defined criteria to classify CLL-cell samples in a validation cohort of 705 patients. When the threshold of CD38 (greater or equal to 34%) was applied to stratify patients in this cohort, the 374 patients with CLL cells that were CD38-negative had a median time to first treatment of 5.7 years, whereas the 333 patients with CD38-positive CLL cells had a median time to first treatment of 4.0 years (p<0.001) ( Table 1) . On the other hand, 331 patients in the validation who had ZAP-70-negative CLL cells had a median time from diagnosis to initial therapy of 8.4 years, whereas the 374 patients with CLL cells found ZAP-70 positive had a median time from diagnosis to therapy of 2.6 years (p<0.001). Similarly, 251 patients in the validation cohort were found to use mutated IGHV (M-IGHV). These patients had a significantly longer time to first treatment than did 454 patients with CLL cells in the validation cohort found to use unmutated IGHV (U-IGHV) (namely 8.6 years versus 3.8 years, p<0.001) ( Table 1) . In univariate analysis, the Cox proportional hazard ratio (HR) associated with expression of ZAP-70 for the entire validation cohort was 4.08 (p<0.001), the HR associated with U-IGHV was 3.14 (p<0.001), and the HR associated with expression of CD38 was 1.53 (p<0.001) ( Table 2 ). These HRs were similar for the subset of 521 patients in the validation cohort who enrolled into the CRC prior to initial therapy ( Table   2 ). The HR associated with the expression of ZAP-70 was 5.36 (p<0.001), the HR associated with use of U-IGHV was 3.76 (p<0.001), and the HR associated with the expression of CD38 was 1.51 (p<0.01).
Relative Prognostic Value Of CD38, ZAP-70, And IGHV Mutation Status
We examined the time from diagnosis to initial therapy of patients segregated by their leukemia-cell expression of ZAP-70 into subgroups that then were segregated by CLL- In a multivariable analysis, the Cox proportional HR associated with expression of ZAP-70 (4.08) was not substantially altered when either the expression of U-IGHV or For personal use only. on October 3, 2017. by guest www.bloodjournal.org From CD38 was added to the model (3.09 and 3.96, respectively) ( Table 2) . Likewise, the HR associated with expression of ZAP-70 was significant when both expression of U-IGHV and CD38 were added to the model (HR=3.01, p<0.001) ( Table 2 ). However, the HR associated with expression of U-IGHV (HR=3.14) was reduced to 1.87 when ZAP-70 was added to the model, but not altered when CD38 was added to the model (HR=3.05) ( Table 2 ). The low HR associated with CD38 (HR=1.53) became trivial when ZAP-70 was added to the model (HR=1.14, P=0.25) ( Table 2 ) and was lowered slightly when IGHV mutation status was added to the model (HR=1.39, p=0.002) ( Table   2 ).
A similar hierarchy of HRs was noted for the subset of 152 patients in the validation cohort who were over 65 years of age at diagnosis (Table 2) . These patients had a median age at diagnosis of 70, which is comparable to the median age of all patients diagnosed with CLL
28
. For these patients the HR associated with expression of ZAP-70 (2.79) was not substantially altered when either the expression of U-IGHV or CD38 was added to the model (2.41 and 2.84, respectively) ( Table 2) . Likewise, the HR associated with expression of ZAP-70 was significant when both expression of CD38 and U-IGHV were added to the model (HR=2.47, p<0.001) ( Table 2 ). However, the HR associated with expression of U-IGHV (HR=2.14) was reduced to 1.43 when ZAP-70 was added to the model, but not altered when CD38 was added to the model (HR=2.15) ( Table 2 ). The low HR associated with CD38 (HR=1.08) remained trivial when ZAP-70 or IGHV mutation status was added to the model (Table 2 ). This analysis revealed that the relative strengths of each of these markers in predicting the need for early therapy noted in the entire validation cohort also applied for the subgroup In multivariable analysis, the relative strength of CLL-cell expression of ZAP-70 in predicting early treatment also was apparent for the 521 patients in the validation cohort who had blood samples collected prior to initial therapy. Moreover, in this subset of patients, the HR associated with CLL-cell expression of ZAP-70 appeared highest for patients with low-risk or high-risk Rai-stage disease, but comparable to the HR associated with use of U-IGHV for patients with intermediate-risk Rai-stage disease (Table 2 ). However, the HR associated with CLL-cell expression of CD38 was the lowest in all subgroups, regardless of stage (Table 2) .
We also performed an analysis on the 199 patients in the validation cohort who Table 2) .
Relationship Between CLL-cell Expression of ZAP-70 And IGHV Mutation Status
Using only CLL-cell expression of ZAP-70 or IGHV mutation status, we could segregate patients into three subgroups that differed in their median times from 
Relationship Between High-risk Genetic Features and CLL-cell Expression of ZAP-70
Or U-IGHV We examined the relationship between these prognostic markers and high-risk genetic features in the 323 patients in the validation cohort for whom we had cytogenetic data.
Similar to the findings on the entire validation cohort, patients with CLL cells that expressed ZAP-70 ( Figure 3D ) had a significantly shorter time from diagnosis to initial therapy than did cases that lacked expression of ZAP-70, regardless of the IGHV For
DISCUSSION
In this study we applied criteria for expression of ZAP-70, CD38, and IGHV mutation status defined in a test cohort to segregate patients in a validation cohort.
Our validation cohort was comprised of CLL patients who were evaluated in a manner similar to that of our test cohort 22 . Thus, the analyses for ZAP-70, CD38, and IGHV mutation status were uniformly performed by the CRC for all 1,012 CLL cases examined. Among these three prognostic markers, we found that ZAP-70 was the strongest marker associated with a relatively short time interval from diagnosis to initial therapy. This was apparent even for the subgroup of 521 patients in the validation cohort who submitted blood samples to the CRC prior to receiving any treatment for CLL (Table 2, Figure 3B ).
The median age at diagnosis of the patients who participated in our validation cohort was 56, which is substantially younger than the median age at diagnosis for 70 all patients with this disease 28 . The younger median age in our cohort reflects the demographics of patients who present to referral centers such as those in the CRC, as no selection for age was used in assigning patients to this study. To determine whether our findings also were relevant to older patients with this disease, we segregated out patients from our validation cohort who were 65 years or older at diagnosis who had a median age at diagnosis of 70 years. We found that the relative strength of each prognostic marker noted for the entire validation cohort also applied for this subgroup of patients with ages comparable to that of most patients with this disease (Table 2) .
To test the predictive value of these markers in defining the time to initial therapy, we also segregated out early-to-intermediate stage patients (Rai stages 0-2) in For personal use only. on October 3, 2017. by guest www.bloodjournal.org From the validation cohort who submitted samples to the CRC within one year of diagnosis prior to receiving therapy for CLL (N = 199). For these 199 patients we found that CLLcell expression of ZAP-70 still maintained its relative predictive value when compared with IGHV mutation status or CLL-cell expression of CD38 (Table 2, Figure 3C ). We , a function that apparently is independent of its kinase activity 33, 34 . This suggests a model proposing that CLL cells that express ZAP-70 are more responsive to self and/or environmental antigens that interact with the highly selected repertoire of Ig used by CLL B cells. Provided that there is repeated exposure to such antigens over time, this could allow for leukemia B cells stimulation leading to enhanced proliferation and/or resistance to apoptosis 25, 30 . If so, then the expression of ZAP-70 might be more closely tied to the propensity for early disease progression than the mutation status of the expressed IGHV.
Some studies have not found ZAP-70 to be an independent risk factor for aggressive disease [35] [36] [37] [38] [39] . Conceivably, this might relate to the methods used for antibodies might be subject to more variation than assays using directly labeled mAbs, further compounding this problem. Moreover, one recent study observed differences in the percent of leukemia cells staining positive for ZAP-70 when different mAbs were used on the same leukemia-cell population, even when the same gating strategy was used in the analysis 45 . As such, analyses using other antibodies for ZAP-70 should be compared with those using the directly labeled IE7. For Here, the reference group in the HR is the set of patients having the adverse marker and an increase risk for early treatment. An asterisk (*) is used to denote HR that have Figure 3 
